Clinical trials: Blindness, open to volunteers
Retinitis Pigmentosa (RP), Usher Syndrome Type 2
Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13…
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
- Trial name
- CAPELLA (NCT07796646)
- Testing
- No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen
- Volunteers
- 81 people
- Sponsor
- Laboratoires Thea
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Retinitis Pigmentosa (RP), Usher Syndrome
24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001.
- Trial name
- NCT07290530
- Testing
- N-acetylcysteine amide
- Volunteers
- 80 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.
Leber Congenital Amaurosis 10, Blindness
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
- Trial name
- HYPERION (NCT06891443)
- Testing
- sepofarsen
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 32 people
- Sponsor
- Laboratoires Thea
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- AQUARIUS (NCT07482176)
- Testing
- Ixo-vec, Aflibercept
- Where
- 79 sites in United States
- Volunteers
- 534 people
- Sponsor
- Adverum Biotechnologies, Inc.
Usher Syndrome, Type 1B
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene.
- Trial name
- NCT06591793
- Testing
- AAVB-081
- Where
- 3 sites in Italy, United Kingdom
- Volunteers
- 15 people
- Sponsor
- AAVantgarde Bio Srl
Retinitis Pigmentosa (RP), Usher Syndrome
Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease.
- Conditions
- Retinitis Pigmentosa (RP), Usher Syndrome, Cone Rod Dystrophy
- Trial name
- TES-STEP (NCT07548944)
- Testing
- Transcorneal Electrical Stimulation using the OkuStim System
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Okuvision GmbH
Keratoprosthesis, Corneal Blindness
Evaluation of the Efficacy and Safety of Aspheric Keratoprosthesis in the Treatment of Patients With Corneal Blindness: A Clinical Study
This is a prospective, multicenter, randomized controlled (1:1) non-inferiority clinical trial. A total of 54 subjects are scheduled to be enrolled at no fewer than 2 study sites in China.
- Trial name
- NCT07526389
- Testing
- Investigational Keratoprosthesis Implantation, Control Medical Device
- Volunteers
- 54 people
- Sponsor
- Shanghai Vision Science Engineer Medical Equipment Co., Ltd
Dry Age-related Macular Degeneration, Vision Impairment and Blindness
Vision Improvement for Legally Blind Dry AMD Patients
This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.
- Trial name
- NCT04875234
- Testing
- Clear-K Low Vision Aid Treatment
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Lower Extremity Edema, Lower Extremity Edema Chronic
Pedal Pump Clinical Trial on Edema V2
Previous research on the osteopathic manual technique entitled "Pedal Pump" has shown health benefits, specifically increasing lymphatic flow, decreasing lower extremity edema, and decreasing serum lactic acid after maximal…
- Conditions
- Lower Extremity Edema, Lower Extremity Edema Chronic, CHF - Congestive Heart Failure, CHF Exacerbation
- Trial name
- NCT07809516
- Testing
- Pedal Pump
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hillcrest
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of…
- Trial name
- NCT07630649
- Testing
- Ixo-vec
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Adverum Biotechnologies, Inc.
Sleep-wake Disorder in Blind Individuals
Patient Registry of Blind Subjects With Sleep-related Problems
Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness.
- Trial name
- NCT01195558
- Testing
- Data collection on blindness and sleep problems
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Vanda Pharmaceuticals
Retinitis Pigmentosa (RP), Usher Syndrome
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001.
- Trial name
- SLORP Preserve (NCT07710196)
- Testing
- NPI-001
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.
Chronic Venous Disease, Chronic Venous Insufficiency, CVI
The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry
The goal of this observational study is to gather additional safety and performance (effectiveness) data on the device for the treatment of symptomatic lower extremity venous obstructions and occlusions.
- Conditions
- Chronic Venous Disease, Chronic Venous Insufficiency, CVI, Venous Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- CALIBER (NCT07529756)
- Testing
- Recanalization and debulking
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Intervene, Inc.
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP)
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor…
- Conditions
- Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD)
- Trial name
- CLARICO (NCT06789445)
- Testing
- OpCT-001
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- BlueRock Therapeutics
Primary Open-Angle Glaucoma (POAG)
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via…
- Trial name
- NCT06921317
- Testing
- GVB-2001-high dose, GVB-2001-low dose
- Where
- China
- Volunteers
- 6 people
- Sponsor
- IVIEW Therapeutics Inc.
Homonymous Hemianopsia, Homonymous Quadrantanopia
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery.
- Trial name
- NCT07185971
- Testing
- PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeuroAEye LLC
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.